<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01888744</url>
  </required_header>
  <id_info>
    <org_study_id>2010/010</org_study_id>
    <nct_id>NCT01888744</nct_id>
  </id_info>
  <brief_title>Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist</brief_title>
  <acronym>Avanti</acronym>
  <official_title>The Effect of the Type of Ovarian Stimulation Protocol on PGD Results: a Prospective Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to define the optimal ovarian stimulation protocol concerning PGD and
      for this reason we plan a randomized controlled trial (RCT) comparing gonadotropin-releasing
      hormone (GnRH) agonist protocol versus GnRH antagonist protocol. The follicle stimulating
      hormone (FSH) preparation in both arms will be highly purified FSH (Menopur®).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized at the outpatient clinic in two groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of day 3 embryos for biopsy available</measure>
    <time_frame>up to 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of mature cumulus-oocyte complexes</measure>
    <time_frame>up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>up to 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Reproductive Endocrinology</condition>
  <condition>Fertility</condition>
  <condition>Optimal Stimulation Protocol</condition>
  <arm_group>
    <arm_group_label>Group 1 (GnRH agonist group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The long GnRH agonist protocol starts on day 21 of the preceding cycle with the administration of GnRH agonist, Decapeptyl® 0,1 mg subcutaneously daily or buserelin acetate, Suprefact® 600 μg daily intranasal. The administration of highly purified human menopausal gonadotropin (hp-HMG), Menopur® 225 IU subcutaneously is started after three weeks of desensitization. The desensitization is checked by ultrasound (absence of cysts) and hormonal measurement (Estradiol levels &lt; 80 pg/ml, FSH ≤ 10 IU/l and progesterone &lt; 1,5ng/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (GnRH antagonist group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ovarian stimulation is started at day 2 of the menstrual cycle with 225 IU of HMG (Menopur ®) subcutaneously. At day 6 of the stimulation GnRH antagonist (Orgalutran®) 0,25 mg subcutaneously is added. Basal hormonal status will be confirmed in the antagonist group before starting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH agonist</intervention_name>
    <arm_group_label>Group 1 (GnRH agonist group)</arm_group_label>
    <other_name>Suprefact nasal spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH antagonist</intervention_name>
    <arm_group_label>Group 2 (GnRH antagonist group)</arm_group_label>
    <other_name>Orgalutran or Cetrotide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hP-hMG</intervention_name>
    <arm_group_label>Group 1 (GnRH agonist group)</arm_group_label>
    <arm_group_label>Group 2 (GnRH antagonist group)</arm_group_label>
    <other_name>Menopur</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human chorionic gonadotropin</intervention_name>
    <description>induction of final oocyte maturation</description>
    <arm_group_label>Group 1 (GnRH agonist group)</arm_group_label>
    <arm_group_label>Group 2 (GnRH antagonist group)</arm_group_label>
    <other_name>Pregnyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <arm_group_label>Group 1 (GnRH agonist group)</arm_group_label>
    <arm_group_label>Group 2 (GnRH antagonist group)</arm_group_label>
    <other_name>Utrogestan vaginal tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≤ 39 years the day of oocyte retrieval

          -  BMI ≤ 29

          -  cycle rank 1

          -  menstrual cycle 25-36 days

          -  PGD or preimplantation genetic screening (PGS) requested

          -  ICSI

          -  Single embryo transfer (SET) on day 5

        Exclusion Criteria:

          -  Polycystic Ovary Syndrome (PCOS) (according Rotterdam criteria)

          -  Hormonal disturbances

          -  Endometriosis grade III and IV
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre for Reproductive Medicine</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2013</study_first_submitted>
  <study_first_submitted_qc>June 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <last_update_submitted>June 27, 2013</last_update_submitted>
  <last_update_submitted_qc>June 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Christophe Blockeel</investigator_full_name>
    <investigator_title>Professor Doctor</investigator_title>
  </responsible_party>
  <keyword>Intracytoplasmic sperm injection (ICSI)</keyword>
  <keyword>PGD</keyword>
  <keyword>GnrH agonist</keyword>
  <keyword>GnRH antagonist</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
    <mesh_term>Ganirelix</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Menotropins</mesh_term>
    <mesh_term>Buserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

